Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy.
Clear Cell Ovarian cancer
Lenvatinib
Pembrolizumab
Recurrent
Treatment-resistant
Journal
Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
10
04
2023
revised:
31
05
2023
accepted:
02
06
2023
medline:
16
6
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
epublish
Résumé
Treatment of ovarian clear cell carcinoma (CCC) poses many challenges. Effective treatment options for recurrent and metastatic disease remain limited. A 70-year-old woman with recurrent metastatic ovarian CCC experienced durable response to the combination of pembrolizumab, a PD-1 targeting monoclonal antibody and lenvatinib, an oral multikinase inhibitor, after failing standard and experimental treatments. She experienced a 40.1% reduction of target lesions over 26 weeks of therapy. CA-125 trends confirmed serial CT scan findings of shrinking disease burden. She experienced overall mild side effects from the drug combination, and lenvatinib dosage was decreased from 20 to 10 mg/day over her 10 cycles. The combination of pembrolizumab and lenvatinib may represent a new treatment option for chemotherapy-resistant ovarian CCC.
Sections du résumé
Background
UNASSIGNED
Treatment of ovarian clear cell carcinoma (CCC) poses many challenges. Effective treatment options for recurrent and metastatic disease remain limited.
Case
UNASSIGNED
A 70-year-old woman with recurrent metastatic ovarian CCC experienced durable response to the combination of pembrolizumab, a PD-1 targeting monoclonal antibody and lenvatinib, an oral multikinase inhibitor, after failing standard and experimental treatments. She experienced a 40.1% reduction of target lesions over 26 weeks of therapy. CA-125 trends confirmed serial CT scan findings of shrinking disease burden. She experienced overall mild side effects from the drug combination, and lenvatinib dosage was decreased from 20 to 10 mg/day over her 10 cycles.
Conclusion
UNASSIGNED
The combination of pembrolizumab and lenvatinib may represent a new treatment option for chemotherapy-resistant ovarian CCC.
Identifiants
pubmed: 37325296
doi: 10.1016/j.gore.2023.101218
pii: S2352-5789(23)00087-5
pmc: PMC10265468
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101218Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Gynecol Oncol. 2020 Mar;156(3):575-582
pubmed: 31955859
Int J Gynecol Cancer. 2023 Mar 6;33(3):385-393
pubmed: 36878571
Nat Med. 2018 May;24(5):556-562
pubmed: 29736026
Clin Cancer Res. 2011 Mar 15;17(6):1521-34
pubmed: 21411445
Gynecol Oncol. 2021 Sep;162(3):619-625
pubmed: 34272090
Int J Gynecol Pathol. 2018 Jul;37(4):388-396
pubmed: 28796747
Gynecol Oncol. 2018 Aug;150(2):247-252
pubmed: 29921512
N Engl J Med. 2022 Feb 3;386(5):437-448
pubmed: 35045221
J Clin Oncol. 2020 Jun 1;38(16):1814-1823
pubmed: 32275468
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Clin Cancer Res. 2018 Jul 15;24(14):3282-3291
pubmed: 29351920
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
Am J Pathol. 2009 May;174(5):1597-601
pubmed: 19349352
Int J Gynecol Cancer. 2017 Jan;27(1):50-58
pubmed: 27749456
Clin Cancer Res. 2013 Mar 1;19(5):961-8
pubmed: 23307860
Sci Rep. 2019 Nov 28;9(1):17808
pubmed: 31780705